PLx Pharma, Inc. (PLXP): Price and Financial Metrics
PLXP Price/Volume Stats
|Current price||$0.02||52-week high||$0.04|
|Prev. close||$0.00||52-week low||$0.02|
|Day high||$0.04||Avg. volume||0|
|50-day MA||$0.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||603.16K|
PLXP Stock Price Chart Interactive Chart >
PLx Pharma, Inc. (PLXP) Company Bio
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company developing aspirin products that use its patented drug delivery system, which targets delivery of APIs to various portions of the gastrointestinal tract. This has the potential to improve the absorption of many drugs and to reduce acute GI side effects associated with aspirin and ibuprofen, and potentially other drugs.
PLXP Latest News Stream
|Loading, please wait...|
PLXP Latest Social Stream
View Full PLXP Social Stream
Latest PLXP News From Around the Web
Below are the latest news stories about PLX PHARMA INC that investors may wish to consider to help them evaluate PLXP as an investment opportunity.
Shopify (SHOP) stock is on the move Wednesday following a price target and new rating from JP Morgan analyst Andrew Boone.
Pre-market stock movers are a hot topic on Wednesday as we dive into all of the latest news affecting markets this morning.
National CineMedia (NCMI) stock is on a wild ride Wednesday morning as investors react to restructuring news and a bankruptcy filing.
PLx Pharma (PLXP) stock continues to fall on Wednesday as the company gets closer to being delisted from the Nasdaq Exchange.
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the “APA”) with PLx Acquisition Company, LLC, a wholly-owned subsidiary
PLXP Price Returns